scout
|Videos|October 20, 2022

Niraparib Maintenance Therapy in Ovarian Cancer: The PRIMA Trial

Robert L. Coleman, MD, FACOG, FACS, describes data updates from the PRIMA trial investigating PARP inhibition in HRD-negative ovarian cancer populations.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME